Highlights

I think patients like more durable agents, and physicians like it too. So, I think that does play a pretty big role. I think patients who require more frequent therapies are certainly looking for alternative therapies with longer duration. So, it does factor into my decisions pretty significantly.

Right now, intravitreal seems to be the main route of administration for now. PDS, I think, is still early on, certainly I think it’s a very effective treatment, it’s very durable, and certainly I think the idea of longer acting is a good one, but right now it hasn’t taken off very much, and very specific patients are on PDS, but I think right now intravitreal seems to be the major route currently.

I do think the hope is that we identify a different target, for example Vabysmo was recently approved with a dual mechanism of targeting action with Ang2 and anti-VEGF, and we’re hoping that in the future we have additional targets, so that we can have even more durability, more efficacy. I guess probably that’s the hope there. But certainly things like gene therapies, and other routes of administration like suprachoroidal, or other long-acting drugs, are very possible in the next 10 years.